
Anne L. Holleran
Examiner (ID: 1384, Phone: (571)272-0833 , Office: P/1642 )
| Most Active Art Unit | 1642 |
| Art Unit(s) | 1643, 1642 |
| Total Applications | 775 |
| Issued Applications | 297 |
| Pending Applications | 125 |
| Abandoned Applications | 356 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 348958
[patent_doc_number] => 07495074
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2009-02-24
[patent_title] => 'Isolated proteins MAGE-4 and MAGE-41'
[patent_app_type] => utility
[patent_app_number] => 11/253240
[patent_app_country] => US
[patent_app_date] => 2005-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 20
[patent_no_of_words] => 16456
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/495/07495074.pdf
[firstpage_image] =>[orig_patent_app_number] => 11253240
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/253240 | Isolated proteins MAGE-4 and MAGE-41 | Oct 16, 2005 | Issued |
Array
(
[id] => 4866310
[patent_doc_number] => 20080145369
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2008-06-19
[patent_title] => 'Autocrine Growth Factor Receptors and Methods'
[patent_app_type] => utility
[patent_app_number] => 11/665359
[patent_app_country] => US
[patent_app_date] => 2005-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 4882
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0145/20080145369.pdf
[firstpage_image] =>[orig_patent_app_number] => 11665359
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/665359 | Autocrine Growth Factor Receptors and Methods | Oct 11, 2005 | Abandoned |
Array
(
[id] => 177923
[patent_doc_number] => 07655631
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2010-02-02
[patent_title] => 'Pharmaceutical preparations and methods for inhibiting tumors'
[patent_app_type] => utility
[patent_app_number] => 11/240937
[patent_app_country] => US
[patent_app_date] => 2005-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 30
[patent_figures_cnt] => 34
[patent_no_of_words] => 25522
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/655/07655631.pdf
[firstpage_image] =>[orig_patent_app_number] => 11240937
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/240937 | Pharmaceutical preparations and methods for inhibiting tumors | Sep 29, 2005 | Issued |
Array
(
[id] => 5813110
[patent_doc_number] => 20060083739
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2006-04-20
[patent_title] => 'Treating prostate cancer with anti-ErbB2 antibodies'
[patent_app_type] => utility
[patent_app_number] => 11/234586
[patent_app_country] => US
[patent_app_date] => 2005-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 23
[patent_no_of_words] => 31526
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0083/20060083739.pdf
[firstpage_image] =>[orig_patent_app_number] => 11234586
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/234586 | Treating prostate cancer with anti-ErbB2 antibodies | Sep 22, 2005 | Abandoned |
Array
(
[id] => 5742815
[patent_doc_number] => 20060088540
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2006-04-27
[patent_title] => 'Antagonists and methods for inhibiting angiogenesis'
[patent_app_type] => utility
[patent_app_number] => 11/227524
[patent_app_country] => US
[patent_app_date] => 2005-09-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 33
[patent_figures_cnt] => 33
[patent_no_of_words] => 16317
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0088/20060088540.pdf
[firstpage_image] =>[orig_patent_app_number] => 11227524
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/227524 | Antagonists and methods for inhibiting angiogenesis | Sep 14, 2005 | Issued |
Array
(
[id] => 5720761
[patent_doc_number] => 20060073536
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2006-04-06
[patent_title] => 'Immunoassays for determining vitamin B12, and reagents and kits therefor'
[patent_app_type] => utility
[patent_app_number] => 11/225818
[patent_app_country] => US
[patent_app_date] => 2005-09-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 5973
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0073/20060073536.pdf
[firstpage_image] =>[orig_patent_app_number] => 11225818
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/225818 | Immunoassays for determining vitamin B12, and reagents and kits therefor | Sep 12, 2005 | Abandoned |
Array
(
[id] => 4547776
[patent_doc_number] => 07820180
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2010-10-26
[patent_title] => 'Listeria-based and LLO-based vaccines'
[patent_app_type] => utility
[patent_app_number] => 11/223945
[patent_app_country] => US
[patent_app_date] => 2005-09-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 17
[patent_no_of_words] => 18758
[patent_no_of_claims] => 62
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/820/07820180.pdf
[firstpage_image] =>[orig_patent_app_number] => 11223945
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/223945 | Listeria-based and LLO-based vaccines | Sep 12, 2005 | Issued |
Array
(
[id] => 5727497
[patent_doc_number] => 20060058257
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2006-03-16
[patent_title] => 'Influencing angiogenesis using CD66a'
[patent_app_type] => utility
[patent_app_number] => 11/224162
[patent_app_country] => US
[patent_app_date] => 2005-09-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 7684
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0058/20060058257.pdf
[firstpage_image] =>[orig_patent_app_number] => 11224162
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/224162 | Influencing angiogenesis using CD66a | Sep 11, 2005 | Abandoned |
Array
(
[id] => 5710004
[patent_doc_number] => 20060051349
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2006-03-09
[patent_title] => 'Immunotherapy of autoimmune disorders using antibodies which target B-cells'
[patent_app_type] => utility
[patent_app_number] => 11/222838
[patent_app_country] => US
[patent_app_date] => 2005-09-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7355
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0051/20060051349.pdf
[firstpage_image] =>[orig_patent_app_number] => 11222838
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/222838 | Immunotherapy of autoimmune disorders using antibodies which target B-cells | Sep 11, 2005 | Issued |
Array
(
[id] => 344845
[patent_doc_number] => 07498030
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2009-03-03
[patent_title] => 'Treatment with anti-ErbB2 antibodies and anti-hormonal compounds'
[patent_app_type] => utility
[patent_app_number] => 11/222587
[patent_app_country] => US
[patent_app_date] => 2005-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 21
[patent_no_of_words] => 36344
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/498/07498030.pdf
[firstpage_image] =>[orig_patent_app_number] => 11222587
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/222587 | Treatment with anti-ErbB2 antibodies and anti-hormonal compounds | Sep 8, 2005 | Issued |
Array
(
[id] => 5799311
[patent_doc_number] => 20060034842
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2006-02-16
[patent_title] => 'Treatment with anti-ErbB2 antibody combinations'
[patent_app_type] => utility
[patent_app_number] => 11/223361
[patent_app_country] => US
[patent_app_date] => 2005-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 36349
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0034/20060034842.pdf
[firstpage_image] =>[orig_patent_app_number] => 11223361
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/223361 | Treatment with anti-ErbB2 antibody combinations | Sep 8, 2005 | Issued |
Array
(
[id] => 4484510
[patent_doc_number] => 07883702
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2011-02-08
[patent_title] => 'Use of anti-mortalin 2 antibody and functional nucleic acid for cancer therapies'
[patent_app_type] => utility
[patent_app_number] => 11/661134
[patent_app_country] => US
[patent_app_date] => 2005-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 36
[patent_no_of_words] => 17005
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 8
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/883/07883702.pdf
[firstpage_image] =>[orig_patent_app_number] => 11661134
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/661134 | Use of anti-mortalin 2 antibody and functional nucleic acid for cancer therapies | Aug 24, 2005 | Issued |
Array
(
[id] => 4634022
[patent_doc_number] => 08012470
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2011-09-06
[patent_title] => 'Method for ex vivo immunization using heterologous intact bispecific and/or trispecific antibodies'
[patent_app_type] => utility
[patent_app_number] => 11/186136
[patent_app_country] => US
[patent_app_date] => 2005-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 6801
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/08/012/08012470.pdf
[firstpage_image] =>[orig_patent_app_number] => 11186136
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/186136 | Method for ex vivo immunization using heterologous intact bispecific and/or trispecific antibodies | Jul 19, 2005 | Issued |
Array
(
[id] => 5767787
[patent_doc_number] => 20060019344
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2006-01-26
[patent_title] => 'C-erbB-2 external domain: gp75'
[patent_app_type] => utility
[patent_app_number] => 11/175405
[patent_app_country] => US
[patent_app_date] => 2005-07-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 20586
[patent_no_of_claims] => 64
[patent_no_of_ind_claims] => 23
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0019/20060019344.pdf
[firstpage_image] =>[orig_patent_app_number] => 11175405
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/175405 | C-erbB-2 external domain: gp75 | Jul 6, 2005 | Abandoned |
Array
(
[id] => 363204
[patent_doc_number] => 07482014
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2009-01-27
[patent_title] => 'Melanoma therapy'
[patent_app_type] => utility
[patent_app_number] => 11/166862
[patent_app_country] => US
[patent_app_date] => 2005-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4341
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 77
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/482/07482014.pdf
[firstpage_image] =>[orig_patent_app_number] => 11166862
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/166862 | Melanoma therapy | Jun 23, 2005 | Issued |
Array
(
[id] => 215113
[patent_doc_number] => 07618631
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2009-11-17
[patent_title] => 'Treatment with anti-ErbB2 antibodies and EGFR-targeted drugs'
[patent_app_type] => utility
[patent_app_number] => 11/154465
[patent_app_country] => US
[patent_app_date] => 2005-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 21
[patent_no_of_words] => 35925
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/618/07618631.pdf
[firstpage_image] =>[orig_patent_app_number] => 11154465
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/154465 | Treatment with anti-ErbB2 antibodies and EGFR-targeted drugs | Jun 15, 2005 | Issued |
Array
(
[id] => 5793138
[patent_doc_number] => 20060013819
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2006-01-19
[patent_title] => 'Therapy of platinum-resistant cancer'
[patent_app_type] => utility
[patent_app_number] => 11/154337
[patent_app_country] => US
[patent_app_date] => 2005-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 20
[patent_no_of_words] => 32031
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0013/20060013819.pdf
[firstpage_image] =>[orig_patent_app_number] => 11154337
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/154337 | Therapy of platinum-resistant cancer | Jun 14, 2005 | Abandoned |
Array
(
[id] => 7069034
[patent_doc_number] => 20050244417
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2005-11-03
[patent_title] => 'Apo-2 ligand-anti-Her-2 antibody synergism'
[patent_app_type] => utility
[patent_app_number] => 11/153056
[patent_app_country] => US
[patent_app_date] => 2005-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 14826
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0244/20050244417.pdf
[firstpage_image] =>[orig_patent_app_number] => 11153056
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/153056 | Apo-2 ligand-anti-Her-2 antibody synergism | Jun 14, 2005 | Abandoned |
Array
(
[id] => 5368385
[patent_doc_number] => 20090305944
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-12-10
[patent_title] => 'Methods for Providing Palliative Care with AVR 118'
[patent_app_type] => utility
[patent_app_number] => 11/921484
[patent_app_country] => US
[patent_app_date] => 2005-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6601
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0305/20090305944.pdf
[firstpage_image] =>[orig_patent_app_number] => 11921484
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/921484 | Methods for Providing Palliative Care with AVR 118 | Jun 2, 2005 | Abandoned |
Array
(
[id] => 7111112
[patent_doc_number] => 20050208567
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2005-09-22
[patent_title] => 'Reagents and methods useful for detecting diseases of the prostate'
[patent_app_type] => utility
[patent_app_number] => 11/122741
[patent_app_country] => US
[patent_app_date] => 2005-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 33914
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0208/20050208567.pdf
[firstpage_image] =>[orig_patent_app_number] => 11122741
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/122741 | Reagents and methods useful for detecting diseases of the prostate | May 4, 2005 | Abandoned |